Home / Market News / $SPTX

$SPTX news and market catalysts

The 9 most recent market catalysts affecting $SPTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 1 high impact 1 bullish 1 bearish Biotechnology
Oct 14, 2026 Corporate Catalyst Neutral Impact 65
Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28
Canaccord Genuity's initiation of coverage on Seaport Therapeutics (SPTX) with a 'Buy' rating and a $28 price target is a significant event for the company. Analyst coverage, espec…
Oct 8, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This action signals that the analyst's investme…
Sep 10, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This action signals continued confidence from a pro…
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Seaport Therapeutics reported positive Phase 1 results for GlyphAllo, demonstrating that the drug did not impair next-morning driving performance at either 375 mg or 250 mg doses. …
Aug 26, 2026 Corporate Catalyst Neutral Impact 65
Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32
Jones Trading analyst Justin Walsh has initiated coverage on Seaport Therapeutics (SPTX) with a 'Buy' rating and a $32 price target. This event is significant for SPTX as new analy…
Aug 20, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This action signals continued confidence from a…
Aug 4, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $50 price target for Seaport Therapeutics (SPTX). This is a routine but positive development, as …
Aug 3, 2026 Corporate Catalyst Bearish Impact 95
Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate
Seaport Therapeutics (SPTX) announced Q2 losses of $(1.78) per share, which is a substantial miss compared to the analyst consensus estimate of $(0.65). This 173.85% miss indicates…
Jul 15, 2026 Corporate Catalyst Neutral Impact 75
HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. initiating coverage on Seaport Therapeutics with a 'Buy' rating and a $50 price target is a strong positive signal for the company. This analyst endorsement can…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.